Funding for this research was provided by:
Instituto de Salud Carlos III (PI13/00456, PI15/00829, PI16/00337, CP14/00121)
European Regional Development Fund
Centre for Industrial Technological Development (IDI-20151125)
Centro Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas
Ministerio de Economía y Competitividad (BFU-2011-23604, SAF2014-52400-R, SAF2017-87846-R)
Consejería de Educación, Juventud y Deporte, Comunidad de Madrid (S2013/ABI-2906)
Plan Estratégico Nacional contra la Hepatitis C
Received: 20 February 2018
Accepted: 23 August 2018
First Online: 3 September 2018
Ethics approval and consent to participate
: Use of anonymized serum samples from patients was approved by the Clinical Research Ethics Committee at Vall d’Hebron Institut of Research, according to the regulation BPC (CPMP/ICH/135/95), and with the Spanish Real Decreto 1090/2015. Written informed consent was obtained from all patients.
: Written informed consent for publication was obtained.
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.